High Altitude Pulmonary Hypertension
Conditions
Keywords
Pulmonary Hypertension, Hypoxia, High Altitude, Sleep disordered breathing
Brief summary
To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanders with High Altitude Pulmonary Hypertension (HAPH) who permanently live \>2500m on sleep disordered breathing
Detailed description
This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA \>30 mmHg who permanently live at HA \>2500 m will have nocturnal respiratory sleep studies near their living altitude in Aksay at 3200 m and on night 1 and 6 at 760m after relocation.
Interventions
OTHERSDB assessment
SDB will be assessed by respiratory polygraphy according to clinical standards
Sponsors
University of Zurich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Each highlander with HAPH will be assessed for SDB at 3200 m and at 760 m according to a prospective study design
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Permanently living \>2500 m * HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m * Written informed consent
Exclusion criteria
* Highlanders who cannot follow the study investigations, * Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years. * Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean nocturnal SpO2 during the first night at LA vs HA | night 1 at 760 m compared to 3200 m. | Change in mean nocturnal SpO2 (%) between LA (760 m) vs HA (3200 m) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean nocturnal SpO2 during the sixth night at LA vs HA | night 6 at 760 m compared to 3200 m. | Change in mean nocturnal SpO2 (%) between LA (760 m) vs HA (3200 m) |
| Time spent with SpO2<90% at LA vs HA | night 1 and night 6 at 760 m compared to 3200 m. | Change in time spent with SpO2\<90% between LA (760 m) vs HA (3200 m) |
| AHI at LA vs HA | night 1 and night 6 at 760 m compared to 3200 m. | Change in apnea-hypopnea index (AHI) between LA (760 m) vs HA (3200 m) |
| ODI at LA vs. HA | night 1 and night 6 at 760 m compared to 3200 m. | Change in oxygen desaturation index (ODI) between LA (760 m) vs HA (3200 m) |
| Time spent with periodic breathing at LA vs. HA | night 1 and night 6 at 760 m compared to 3200 m. | Change in time spent with periodic breathingbetween LA (760 m) vs HA (3200 m) |
| Heart rate variability at LA vs. HA | night 1 and night 6 at 760 m compared to 3200 m. | Change in heart rate variability between LA (760 m) vs HA (3200 m) |
| ECG markers of repolarization at LA vs. HA | night 1 and night 6 at 760 m compared to 3200 m. | Change in electrocardiogram (ECG) markers of repolarization (QT time) between LA (760 m) vs HA (3200 m) |
| pulse transit time drops at LA vs. HA | night 1 and night 6 at 760 m compared to 3200 m. | Change in pulse transit time drops between LA (760 m) vs HA (3200 m) |
Countries
Kyrgyzstan
Contacts
PRINCIPAL_INVESTIGATORTalant M Sooronbaev, Prof. Dr.
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
PRINCIPAL_INVESTIGATORSilvia Ulrich, Prof. Dr.
University Hospital Zurich, Department of Pulmonology
Outcome results
None listed